Common Chemicals May Harm Sperm and Pregnancies, Growing Evidence Shows


Chemicals called phthalates—found in everything from detergent to plastic shower curtains—are tied to lower sperm counts and more miscarriages.

Common Chemicals May Harm Sperm and Pregnancies, Growing Evidence Shows

Epidemiologist Carmen Messerlian does her best to avoid potentially harmful chemicals. As she glanced around her home a few days before the new year began, she took inventory of her seasonal exposure to substances called phthalates, which are widely used to make plastic more flexible and durable. They also bind fragrances to products ranging from candles to laundry detergent and cosmetics. “I’m anticandle,” she said, but she had three or four scenting her home. It was, after all, the season. Then there were the soft plastic earbuds she had picked up at an airport and the shiny enamel sparkling on her fingernails. “You break all your rules over the holidays because you want to look good and you want your house to look and smell nice.” But she certainly knows better.

At Harvard University’s T. H. Chan School of Public Health, Messerlian has conducted more than a dozen studies indicating that certain phthalates impair reproductive health. Her work, and that of many others, has demonstrated that men with higher concentrations of phthalates in their urine (a measure of exposure) have lower sperm counts and poorer sperm motility than men with less of these substances. Women with high levels of exposure are more likely to have fertility problems, miscarriages, preterm labor and low-birth-weight babies. Recent research also implicates the chemicals in the growth of uterine fibroids—noncancerous tumors that can cause pain, bleeding, diminished fertility and pregnancy complications. In 2017 the U.S. government banned the use of certain phthalates in toys because they were linked to changes in male genital tract development, but regulatory agencies have been slow to limit their use in other products. As evidence of harm continues to build, many researchers see a need for greater regulation and more public awareness.

The case against phthalates is complicated because researchers cannot ethically expose people to the chemicals in order to study the effects. The evidence is therefore based on animal research and observational data among humans, including decades of studies comparing health outcomes among people with higher versus lower levels of exposure. Adding to the complexity are the large variety of phthalates, the difficulty in separating their effects from those of other environmental chemicals that similarly disrupt human hormones and reproductive tissues, and the advent of phthalate substitutes that are not necessarily safer than the originals.

There are certain windows of time when phthalate exposure is particularly concerning, research suggests. These include the preconception period when eggs and sperm mature, pregnancy and gestation, and early childhood. Last year a large study led by Kelly Ferguson of the National Institute of Environmental Health Sciences found that high exposure to each of four types of phthalates during pregnancy was associated with a 12 to 16 percent increase in the probability of giving birth three or more weeks early—which can put newborns at risk. The study, which pooled data from more than 6,000 pregnancies, was the largest ever to examine the issue, Ferguson says. It is also one of the first “to address this question in a diverse population,” she says, an important consideration because lower-income and marginalized minorities appear to have greater exposure to the chemicals. She and her colleagues estimate that cutting the study group’s exposure to phthalates in half would have reduced the incidence of preterm births from 90 per 1,000 live births to 79 per 1,000.

To achieve a reduction in phthalates, “we need a multipronged approach,” says Russ Hauser, an expert on phthalates and reproductive health at Harvard. “That includes federal regulations to reduce and ban their use, increased public knowledge so people can make informed decisions, and more transparent labeling of consumer products.” The Food and Drug Administration is currently reviewing the safety of phthalates in plastics used to process and wrap food. The Environmental Protection Agency is still determining how best to evaluate the risks posed by phthalates. But the regulatory process moves at a sluggish pace.

Messerlian suggests that people can lower their exposure by making small changes in their homes and habits, such as replacing scented detergents and skin creams with fragrance-free varieties and buying cold cuts wrapped in paper at a deli counter rather than items prepackaged in plastic. Such actions also can pressure industry to make safer products. Messerlian’s website, seed-program.org, offers other tips for reducing exposure. “Even if you swap out one or two things,” she says, “that’s a win.”

Post-Transplant LN Patients Can Have Viable Pregnancies


Outcomes better in women with inactive systemic lupus erythematosus..

Having a renal transplant for lupus nephritis did not rule out successful pregnancies, but outcomes were better in those whose systemic lupus erythematosus (SLE) was inactive, according to an Italian case report.

The researchers, led by Gabriella Moroni, MD, of the Ospedale Maggiore IRCCS, in Milan, analyzed nine pregnancies in three of 38 women who had received kidney transplants at their center. Two patients had received a kidney from a living related donor and one had a received a transplant from a deceased donor.

From 2002 to 2013, five of these post-transplant pregnancies ended in miscarriage. All mothers were in their 30s by the time they conceived, and their initial pregnancies occurred at 4 years, more than 7 years, and almost 9 years after transplantation. In the last case, after two miscarriages, the woman had her first successful pregnancy more than 10 years’ post-transplant at age 38, the group wrote online in Lupus.

Miscarriages in transplanted patients are common, and preconception counseling is essential, the investigators noted.

“Women with stable and prolonged remission of SLE, normal renal function, normal blood pressure, and negative antiphospholipid antibodies (aPL) have good probabilities of positive fetal and maternal outcomes,” they explained.

However, they added that very few cases of post-transplant pregnancy in lupus nephritis (LN) patients have been reported in the literature.

In their study, patients were followed at least once a month and then followed twice weekly from 24 weeks’ gestation onward (including with serial placental Doppler imaging), hospitalized when necessary, and cared for by a multidisciplinary team of gynecologists and nephrologists.

All infants were delivered via cesarean, and the majority were of low birth rate, which may have been partly due to early surgical delivery, the authors explained. However, the infants were healthy and without serious complications, they added.

Immunosuppressive therapy consisted of steroids, calcineurin inhibitors, and mycophenolate mofetil (MMF), which had been replaced with azathioprine before conception. All patients had normal renal function and urinalysis (serum creatinine <1.5 mg/dL) and nonsignificant proteinuria (<500 mg/day). Some signs of immunological activity persisted after transplantation in two patients.

The authors stressed that before pregnancy, patients’ immunosuppressive regimens must be re-evaluated for possible teratogenic effects. They recommended switching from MMF to azathioprine. Also, ACE inhibitors must be discontinued before or at conception, they advised.

They reported that two pregnancies were uneventful. Pre-eclampsia occurred in a hypertensive patient in two pregnancies that ended in preterm delivery in one and newborns of small-for-gestational-age size in both. The authors ascribed these good results partly to the well-planned pregnancies and the specialized intensive care and imaging.

Significantly, although the risk of post-pregnancy graft loss in transplanted mothers is about around 6.9% within the first 5 years of giving birth, graft function continued to be normal in all patients. “To reduce such a risk it is wise to discourage pregnancy within the first year after transplantation,” they wrote. Urinalysis results also remained normal.

The authors noted that recent studies suggest that hydroxychloroquine improves obstetrical outcomes and should be part of immunosuppressive therapy throughout pregnancy.

“It is also important that patients start low-dose aspirin within the first trimester of pregnancy as primary prophylaxis for pre-eclampsia,” they cautioned.

Based on their experience and on published guidelines for renal transplanted patients, Moroni’s group concluded that “pregnancy in patients with kidney transplant due to LN should not be discouraged,” adding that “pre-conception counseling is mandatory.”

Pregnancy and dialysis.


Survey results suggest lack of clear guidelines leads to uncertainty.

  • Medpage Today

A third of nephrologists reported being somewhat to very uncomfortable caring for a pregnant patient on hemodialysis despite a growing number having to do so, said researchers here.

A small mailed survey found that 43% of nephrologist respondents have cared for a pregnant patient on dialysis, and in 32% of those pregnancies, dialysis was started during the pregnancy. Half of all the pregnancies were complicated by preeclampsia, and 23% of the reported pregnancies did not result in a live birth, said researchers, led by Mala Sachdeva, MD, at the North Shore-Long Island Jewish (LIJ) Health System in Great Neck, N.Y. She reported her results with her colleagues at a poster session during the spring clinical meeting of the National Kidney Foundation.

“We had actually noticed that we were caring for more and more pregnant patients on dialysis, and we had a couple of successful pregnancies and we wanted to see what the U.S. experience was,” said Sachdeva in an interview with MedPage Today. But she said the team was surprised by the outcomes. “They were not great, though there were no reported maternal deaths. It tells us that we need something to work on,” she said.

Data were taken from a survey sent out in May 2014 with 23 questions about the experience of pregnant women on dialysis, fetal outcomes, and current clinical patterns associated with pregnant patients on dialysis. Seventy-five nephrologists responded.

More than 59 pregnancies were reported in the last 5 years, and in 32% of the reported pregnancies, dialysis was started during pregnancy. In 58%, the pregnancy occurred within the first 5 years of being on maintenance dialysis.

Half of the nephrologists or a member of their staff had to counsel a female dialysis patient about contraception, the study found. And three-quarters of respondents didn’t have access to fetal monitoring during dialysis for the patient.

Most of the nephrologists had their pregnant patients on 4 to 4.5 hours of hemodialysis for 6 days a week, and two-thirds of nephrologists targeted a blood urea nitrogen (BUN) of less than 50mg/dL. But there are no clear guidelines on how to dialyze a pregnant women, said Eileen Miller, MD, medical director of dialysis at North Shore-LIJ, toMedPage Today.

The lack of guidelines accounts for a part of why many nephrologists reported being uncomfortable dialyzing a pregnant patient said Miller. Another reason is that pregnant women on dialysis were relatively uncommon. “But as dialysis has gotten better, we’re seeing more of it, and we need better guidelines so people will feel more comfortable. The last studies done looking at pregnant patients were more than 15 years ago,” she said.